Drug Policy Watch · State Brief 2026

Utah

Snapshot (structured)

Adult-use cannabis: Illegal. No legalization; possession of small amounts remains criminal (up to a class B misdemeanor with possible jail time).
Medical cannabis: Legal since 2018 (voter Prop 2, replaced by the legislature's Utah Medical Cannabis Act); operational since 2020.
Home grow: Prohibited for all patients and adults.
Intoxicating hemp / hemp THC: Heavily restricted. HB 54 (2025) bans delta-8, delta-10, HHC, THCP, THCB, and high-THCA hemp products outside the medical system. Utah does not follow the delta-9-only loophole.
Psychedelics: Schedule I and illegal recreationally; limited state-authorized clinical pathways exist (SB 266 hospital pilot, 2024; HB 390 veterans PTSD research, 2026).
Broad decriminalization: No. A 2026 decriminalization bill (HB 253) never got a hearing.
Harm reduction: Naloxone access and a Good Samaritan law in place; fentanyl test strips decriminalized (SB 86, 2023); syringe services operate in several counties.
Governor (party): Spencer Cox (Republican).
Legislature control: Republican supermajorities in both chambers.
Citizen ballot initiatives allowed: Yes, but with a contested history (Prop 2 was overridden by the legislature in 2018; the legislature's reach over initiatives is the subject of ongoing court fights).
Enclosure pressure score: 4/5

Cannabis

Adult-use cannabis is illegal in Utah. There is no legal recreational market and no path to one in current law.

Medical cannabis is legal. Voters approved Proposition 2 in November 2018 (52.75 percent), but the legislature replaced it in a December 2018 special session with the Utah Medical Cannabis Act (HB 3001), a more restrictive framework that survived legal challenge (Ballotpedia; Salt Lake Tribune). Home cultivation is prohibited for patients.

Market structure is a tightly capped, vertically constrained model. Utah caps cultivation licenses at 8 (all issued since 2019) and historically capped pharmacies at 15; the 2025 General Session (HB 54) raised the pharmacy cap by two, to 17, with the new licenses required to be in rural, medically underserved counties. The Licensing Board awarded the first of these new rural licenses (Moab) on December 4, 2025, and the second is to be awarded before January 1, 2027 and restricted to new, unaffiliated businesses (Center for Medical Cannabis 2026 updates; mmjdaily). License-cap and pharmacy figures should be treated as approximate and verified against the regulator, since these numbers shift with each session.

Key 2026 actions (the 2026 General Session has adjourned): HB 389 (Rep. Jennifer Dailey-Provost, House Minority Whip) and SB 121 (Sen. Evan Vickers) passed and took effect May 6, 2026. Together they allow lower-THC product sales at pharmacies, add a state fee on each purchase, create a patient voucher program (a nonprofit distributing monthly $150 vouchers to cardholders enrolled in Medicaid or Medicare), let UDAF regulate label language, allow tribal photo ID for cards, and ease caregiver background-check rules (Center for Medical Cannabis; Fox 13). The bills also move administrative oversight from the Department of Health and Human Services (DHHS) to the Department of Agriculture and Food (UDAF) by January 1, 2027, possibly as early as July 1, 2026. Note: HB 389 and SB 121 are the bill numbers cited by the state regulator; the Fox 13 roundup attributes the geographic-licensing and voucher work to Sen. Vickers, which is consistent but the exact bill-to-provision mapping is partly unconfirmed.

Hemp

Utah is one of the most restrictive states on intoxicating hemp. HB 54 (2025 General Session, effective May 7, 2025) overhauled the cannabinoid regime: as of 2026, delta-8 THC, delta-10 THC, HHC, THCP, THCB, and high-THCA hemp products are illegal to manufacture or sell outside the state's medical cannabis system, with penalties reported up to $5,000. Utah rejects the federal delta-9-only standard; hemp products are legal only if non-intoxicating (cannabisregulations.ai).

Exposure to the federal hemp change is therefore limited but real. The new federal definition takes effect November 12, 2026: it replaces the delta-9-only test with a total-THC standard and adds a roughly 0.4 mg per-container THC cap, effectively banning most intoxicating hemp products nationwide and closing the THCA and delta-8 loopholes (National Law Review; Troutman/Regulatory Oversight). Because Utah already bans these products at the state level, the federal change mostly aligns federal law with Utah's existing posture rather than forcing a major state pivot.

Recent state action in 2026: a bill to ban CBD vape pens passed, and the kratom fight (SB 45, Sen. Mike McKell) ended as a near-ban that allows only pure kratom leaf sales, with manufacturers given until March 2027 to comply (Fox 13; Deseret News).

Psychedelics

Psilocybin, MDMA, and related substances remain Schedule I and illegal for recreational use. Utah has no decriminalization. It has instead opened narrow clinical pathways.

SB 266 (2024, Sen. Kirk Cullimore and Rep. James Dunnigan) created a hospital pilot letting two large systems, Intermountain Health and University of Utah Health, administer psilocybin and MDMA as alternative behavioral-health treatment; it took effect May 1, 2024, sunsets after three years, and requires a report to the legislature by July 1, 2026 (Marijuana Moment; Filter).

2026 action: HB 390, the Veterans PTSD Clinical Research Amendments (chief sponsor Rep. Jennifer Dailey-Provost, with Sen. Kirk Cullimore), was signed by Gov. Cox on March 19, 2026. It authorizes a state-funded, controlled clinical study at the University of Utah's Huntsman Mental Health Institute using MDMA, psilocybin, or 5-MeO-DMT plus trauma-informed psychotherapy for veterans with treatment-resistant PTSD; the study is expected to begin by January 1, 2027 (Psychedelics Today; University of Utah Health).

Broader drug policy

Decriminalization: Utah has not decriminalized cannabis or other drugs. It remains among a shrinking set of states where possession of even a small amount of marijuana can carry jail time (up to about six months under existing law) (Marijuana Moment). HB 301, "Drug Recodification," was enrolled in the 2026 session and reorganizes drug statutes (sponsor unconfirmed; enrolled text).

Harm reduction: Naloxone is available statewide through Utah Naloxone, a Good Samaritan overdose law protects those seeking help, fentanyl test strips were decriminalized via SB 86 (2023, then-Sen. Jennifer Plumb), and syringe service programs operate in several counties (Utah Naloxone; KSL; NEXT Distro). A federal SAMHSA letter dated April 24, 2026 barred federal dollars from funding public fentanyl test strip distribution, which may pressure state-funded programs (search summary, recovered.org and related coverage).

Sentencing and expungement: see Equity and expungement below.

Political landscape

Governor: Spencer Cox (Republican), in office since 2021, reelected 2024 (Ballotpedia). Party control: Republican supermajorities in both the House and Senate, a multi-decade pattern. Key reform-adjacent figures: Rep. Jennifer Dailey-Provost (D), House Minority Whip, is the recurring sponsor of medical cannabis and psychedelic-research bills; Sen. Evan Vickers (R), Senate Majority Leader and a pharmacist, drives medical cannabis structure; Sen. Kirk Cullimore (R) leads psychedelic-access bills; Rep. Grant Amjad Miller (D) is the decriminalization champion (HB 253) but could not get a hearing in 2026; Sen. Mike McKell (R) led the kratom near-ban. Named opponents to broad decriminalization are not individually documented in the sources reviewed; the practical block is the Republican leadership's refusal to hear HB 253. Specific cannabis-related committee assignments are unconfirmed in the sources reviewed; bills route through health/judiciary standing committees.

Ballot initiatives

Utah allows citizen-initiated statutes and constitutional initiatives, but the process is constrained and politically contested. The defining cannabis example is Prop 2 (2018): voters legalized medical cannabis, and the legislature immediately replaced it in special session, a move upheld by the courts (Ballotpedia). More recently, in League of Women Voters v. Utah State Legislature (2024), the Utah Supreme Court affirmed a constitutional right to reform government through initiatives and blocked Amendment D, which the legislature had advanced to reclaim power to amend voter initiatives (LWV; Utah News Dispatch). No pending drug-policy ballot measure was identified in the sources reviewed.

Equity and expungement

Utah's medical cannabis framework has no documented social-equity licensing program; license caps and the rural set-aside favor established and well-capitalized operators, with the one new 2026 license reserved for "new and unaffiliated" businesses being a narrow exception. On records, Utah's Clean Slate law provides automatic expungement for certain class B and C misdemeanors and minor drug-possession convictions after a waiting period (generally five to seven years, with restitution paid and conviction-count limits). After a pause from October 2024 through December 2025, courts resumed automatically identifying and clearing eligible cases on January 1, 2026 (Justia 77-40a-205; Rasa Legal). Benefit accrues to people with old low-level possession convictions; excluded are those with felony drug records, unpaid restitution or court debt, or counts exceeding statutory limits.

Market and barriers

Cultivation licenses capped at 8 (all issued). Pharmacy cap raised to 17 in 2025 (from 15), with new licenses restricted to rural, medically underserved counties; the second new license is to be awarded before January 1, 2027 to a new, unaffiliated business. A per-purchase state fee applies and may be increased by UDAF. Exact application fees, capital requirements, residency rules, and current total licensee counts are not fully captured in the sources reviewed and should be verified against UDAF and the Center for Medical Cannabis (processor cap PMN; Center for Medical Cannabis). Patient counts and detailed market data are published in the state's program data reports (program data); specific 2026 figures are unconfirmed here.

Enclosure read

Utah runs a deliberately enclosed model. Cannabis access is medical-only, home grow is banned, cultivation and pharmacy licenses are hard-capped, and intoxicating hemp is squeezed out of the open market and back toward the licensed system. The actors consolidating are the limited set of capped license-holders and the two large hospital systems granted exclusive psychedelic-research access (Intermountain and University of Utah). The actors fenced out are home growers and small producers (no home cultivation, capped licenses), independent hemp and smoke-shop retailers (HB 54 plus the federal November 12, 2026 change), kratom vendors (SB 45 near-ban), and ordinary possessors (no decriminalization; HB 253 killed without a hearing). The legislature's track record of overriding the Prop 2 initiative and seeking to curb future initiatives adds a structural fence around bottom-up reform. This justifies an enclosure pressure score of 4/5: heavily fenced, with the only relief valves being narrow, state-blessed clinical pilots and a patient voucher program rather than open markets. It is not a 5 because legal medical access, expungement, and harm-reduction tools do exist and are expanding at the margins.

What to watch next

DHHS-to-UDAF transition of medical cannabis oversight: possibly July 1, 2026, completed by January 1, 2027.
Second new rural pharmacy license: to be awarded before January 1, 2027, new and unaffiliated businesses only.
SB 266 psychedelic pilot report due to the legislature by July 1, 2026; the pilot sunsets in 2027.
HB 390 veterans PTSD study expected to begin by January 1, 2027.
Federal hemp definition change effective November 12, 2026 (total-THC standard, per-container cap).
SB 45 kratom manufacturer compliance deadline March 2027.
2027 General Session convenes on the third Monday of January 2027 (reported as January 18, 2027), a 45-day session; expect renewed decriminalization, hemp, and medical cannabis bills.

Regulators

Utah Department of Agriculture and Food (UDAF): cannabis cultivation and processing, and (by January 1, 2027) the full medical cannabis program (ag.utah.gov).
Utah Department of Health and Human Services (DHHS), Center for Medical Cannabis: current patient cards, pharmacies, provider rules; transitioning duties to UDAF (medicalcannabis.utah.gov).
Medical Cannabis Licensing Board and Compassionate Use Board: licensing and special patient approvals.
UDAF also administers hemp regulation; SAMHSA and federal law set the November 2026 hemp definition.

Federal exposure (2026)

Rescheduling and 280E. The DOJ/DEA order signed April 22, 2026 and effective April 28, 2026 (91 FR 22714) moved only FDA-approved cannabis drugs and state-licensed medical cannabis to Schedule III; recreational cannabis stays Schedule I. Because Utah is a medical-only state, its licensed operators sit squarely inside the category that gains relief. The practical win is the end of IRS Section 280E for that medical category, meaning Utah's capped cultivators, processors, and the central-fill pharmacy model can deduct ordinary business expenses and pay tax on net rather than gross income. In Utah's deliberately thin, hard-capped market, that margin relief flows to a small, fixed set of incumbents (8 cultivation licenses, pharmacies capped at 17) rather than to new entrants, since the state, not the federal schedule, controls who holds a license. Schedule III does not legalize cannabis, does not authorize interstate commerce, and does not shield state-licensed businesses from other federal law; it is a tax and research reclassification, not a market opening. The broader DEA hearing opened June 29, 2026 and may slip to 2027, so the medical-only carve-out is the operative change for Utah today (National Law Review).

The November 12, 2026 hemp cliff. The FY2026 agriculture appropriations rider (Sec. 781, Rep. Andy Harris R-MD) narrows the federal hemp definition to a total-THC standard (about 0.4 mg THC per container), recriminalizing an estimated 90 to 95 percent of intoxicating hemp products effective November 12, 2026; the H.R.7010 delay was not enacted and the 2026 Farm Bill (H.R.7567) keeps the ban (bill numbers per federal context; verify against Congress.gov). For Utah the practical effect is reinforcement, not disruption. HB 54 (2025) already banned delta-8, delta-10, HHC, THCP, THCB, and high-THCA hemp products outside the medical system and rejected the delta-9-only loophole, so the federal change mostly aligns national law with Utah's existing posture. The marginal exposure is at the edges: any Utah retailer still selling low-dose or gray-area hemp products under state tolerances loses the federal hemp safe harbor on November 12, 2026, and out-of-state suppliers and interstate shipments into Utah are squeezed nationally. Net effect: the federal ban hardens an enclosure Utah built first, and pushes any residual intoxicating-cannabinoid demand toward the licensed medical channel (Troutman/Regulatory Oversight).

Banking. SAFER Banking remains stalled in Congress, so Utah's licensed medical operators still face restricted access to depository and lending services, higher compliance costs, and cash-handling risk. Schedule III relief on taxes does not fix the banking problem; the two move on separate tracks. In a capped market the banking penalty again favors well-capitalized incumbents who can absorb it and disadvantages any new or rural license-holder (for example the new Moab and forthcoming second rural pharmacy) operating on thinner capital.

Psychedelics. Psilocybin, MDMA, and ibogaine remain Schedule I federally. The April 18, 2026 executive order, Accelerating Medical Treatments for Serious Mental Illness [https://www.whitehouse.gov/presidential-actions/2026/04/accelerating-medical-treatments-for-serious-mental-illness/] plus FDA priority vouchers fast-track FDA review, but there is no federal approval yet. Utah's SB 266 hospital pilot (Intermountain Health and University of Utah Health) and the HB 390 veterans PTSD study at Huntsman Mental Health Institute therefore operate in the narrow space federal law allows for controlled research and clinical administration, not as a state-legal market. These pilots depend on the federal medicalize-and-control pathway: if FDA approval and a rescheduling follow, Utah's hospital-system pilots are positioned to convert into the first sanctioned clinical access, again routing benefit to two large institutions rather than to open practitioners. Until FDA acts, Schedule I status caps what the pilots can do and keeps any broader access illegal.

Harm reduction. SAMHSA guidance dated April 24, 2026 bars federal funds from paying for fentanyl test strips, clean syringes, and sterile water; naloxone remains federally supported. Utah's exposure is direct. Utah decriminalized fentanyl test strips (SB 86, 2023) and runs syringe services in several counties, programs that commonly rely on federal dollars. The federal cut does not outlaw these tools in Utah, but it pulls funding out from under test-strip and syringe distribution, pressuring state and local budgets or forcing reliance on private and state-only money. Naloxone access through Utah Naloxone and the Good Samaritan law are insulated, since naloxone keeps federal support (search summary, recovered.org and related coverage).

Patient access and rights

This section covers what Utah law does and does not protect for a medical cannabis patient: use inside a hospital, and the broader rights that follow a patient into work, housing, parenting, an organ transplant list, and school. It is information, not legal advice, and it reflects the law as of July 2026. Each point links to the primary statute.

Hospital access (Ryan's Law): Utah has no hospital-access law. No statute requires a hospital, nursing home, or hospice to let a qualifying patient use medical cannabis on site, so whether a facility allows it is left to that facility's own policy, and many refuse. Seven states have now enacted a Ryan's Law protection (California in 2021, and Colorado, Delaware, Louisiana, Oregon, Virginia, and Washington in 2026), and Pennsylvania has a bill pending; Utah is not among them. The absence is the finding: a Utah patient has no enforceable right to use their medicine in a hospital today.

Broader protections: Utah protects a patient in three of the six areas, with important limits. Utah Code Section 26B-4-207(1) provides that a patient's use in a medicinal dosage form is treated as the equivalent of any other medication, a general medical-care protection. On employment, Section 26B-4-207(2) reaches public employees only: the state and its political subdivisions must treat medical cannabis like any other prescribed controlled substance, but subsection (4) confirms a private employer is not required to accommodate. Custody and parenting are protected under Utah Code Section 81-9-204. There is no dedicated organ transplant clause; a transplant situation would fall under the general medical-care protection rather than a standalone guarantee. A review found no housing or school protection. Those limits are the finding.

Out-of-state patients: Utah issues a temporary nonresident card, valid for 21 days and available up to twice a year.

The federal picture: the April 2026 federal move of state-licensed medical cannabis to Schedule III did not change any of this. Schedule III does not make dispensary cannabis a lawful prescription medicine and does not create any hospital-use right; only state law can force hospital access, and Utah has not enacted a Ryan's Law. The broader protections above are a creature of Utah law, not federal law.

Sources: Utah patient protections, Utah Code Section 26B-4-207; custody, Utah Code Section 81-9-204.

Analysis: the enclosure read in depth

Who is fenced out in Utah. Utah's model is enclosure by design, not by accident. Cannabis access is medical-only with no recreational path; there is no home grow for any patient or adult; cultivation is hard-capped at 8 licenses and pharmacies at 17, with the state operating a central-fill style, vertically constrained dispensing model. The people and businesses fenced out are consistent across substances: home growers and small craft producers (no cultivation outside the 8 licenses), independent hemp and smoke-shop retailers (HB 54 plus the federal November 12, 2026 ban), kratom vendors (SB 45 near-ban), and ordinary low-level possessors (no decriminalization; HB 253 died without a hearing). Even the psychedelic openings are enclosed, routed exclusively through two large hospital systems rather than independent clinicians. The legislature's Prop 2 override history compounds this: voters passed medical cannabis at the ballot in 2018 and the legislature replaced it in special session with a more restrictive Act, and the legislature has since sought (via the failed Amendment D) to claim power to rewrite future initiatives. That track record fences out the most obvious commons counter-move, bottom-up ballot reform, by signaling that an initiative win can be narrowed by the same supermajority that controls the standing committees.

State-plus-federal interaction. The 2026 federal moves mostly tighten the fence Utah already built. The hemp cliff recriminalizes nationally what Utah banned first, reinforcing the medical channel as the only legal route for intoxicating cannabinoids. Schedule III delivers 280E relief, but only to the fixed roster of state-licensed incumbents, so the federal tax benefit deepens incumbent advantage inside a closed market rather than widening entry. Stalled SAFER Banking and the SAMHSA harm-reduction cuts both press hardest on the thinly capitalized and the publicly funded, which in Utah means new rural licensees and county syringe and test-strip programs. The federal enclosure read, favoring large incumbents and fencing out small actors and hemp, maps almost exactly onto Utah's state structure; the two reinforce rather than offset each other.

What to watch. The DHHS-to-UDAF oversight transition (by January 1, 2027) consolidates regulatory control under agriculture; the second rural pharmacy license (before January 1, 2027, new and unaffiliated only) is the rare pro-entry crack; the SB 266 pilot report (due July 1, 2026) and HB 390 study (by January 1, 2027) will shape whether psychedelic access stays hospital-enclosed; the November 12, 2026 federal hemp cliff and SB 45 kratom compliance (March 2027) finish closing the cannabinoid edges; and the 2027 General Session will test whether decriminalization (likely a renewed HB 253-style bill) can finally get a hearing.

Commons counter-moves. The clearest present counter-move is Clean Slate automatic expungement, which clears certain class B and C misdemeanors and minor drug-possession convictions after a waiting period, with courts resuming automatic clearing on January 1, 2026 after a 2024 to 2025 pause. This is a genuine commons mechanism, returning records and opportunity to ordinary people without requiring them to navigate or pay for the process, though it excludes felony drug records, unpaid restitution, and over-limit counts. Harm reduction (naloxone, Good Samaritan, decriminalized test strips, county syringe services) is a second commons layer, now partly undercut by the SAMHSA funding cut.

Justifying the enclosure score. The 4/5 score holds. Utah pairs a deliberately closed, hard-capped, medical-only, no-home-grow model with an aggressive hemp and kratom ban, no decriminalization, hospital-only psychedelics, and a legislature that has overridden a ballot initiative and tried to fence off future ones. The 2026 federal moves reinforce rather than relax that enclosure. It is not a 5 because real relief valves persist and are even expanding at the margins: legal and growing medical access, a patient voucher program, Clean Slate automatic expungement, a still-supported naloxone and Good Samaritan regime, and one genuinely pro-entry rural license reserved for a new, unaffiliated business. The enclosure is heavy and federally reinforced, but not total.

Active legislation (2026)

The 2026 General Session has adjourned sine die. The table below reflects significant 2026 bills and their outcomes. This list is not exhaustive; for the long tail and live status, see the Utah Legislature 2026 bill list, LegiScan Utah.

Beyond the live tracker

These measures are not in the live bill list below: some are not bills (executive orders, rules, referendums, or budgets), and some are proposals or prior-session measures the live tracker does not currently carry.

HB 390 Veterans PTSD Clinical Research Amendments (psychedelic-assisted therapy study) (Passed; signed March 19, 2026)
HB 301 Drug Recodification (Enrolled)
(unconfirmed bill no.) CBD vape pen ban (Passed)
(unconfirmed bill no.) Expand medical cannabis dispensaries to tribes (Did not advance)
(unconfirmed bill no.) Workers' compensation and medical cannabis patients (No hearing)

Bill	Title/Topic	Chamber	Status	Sponsor(s)
HB 389	Medical cannabis amendments (lower-THC sales, fees, label rules, caregiver checks)	House	Passed; effective May 6, 2026	Rep. Jennifer Dailey-Provost (D)
SB 121	Medical cannabis program (regional licensing, patient vouchers, DHHS-to-UDAF transition)	Senate	Passed; effective May 6, 2026	Sen. Evan Vickers (R) (attribution per Fox 13; exact provision mapping unconfirmed)
HB 253	Marijuana Use or Possession Penalty Amendments (first-offense up to 14 g to civil infraction, fine up to $750, no jail)	House	Introduced; never received a hearing (dead for 2026)	Rep. Grant Amjad Miller (D)
HB 390	Veterans PTSD Clinical Research Amendments (psychedelic-assisted therapy study)	House	Passed; signed March 19, 2026	Rep. Jennifer Dailey-Provost (D); Sen. Kirk Cullimore (R)
SB 45	Kratom Adjustments (modified to a near-ban; pure leaf only)	Senate	Passed; manufacturer compliance by March 2027	Sen. Mike McKell (R)
HB 387	Kratom regulation (alternative House approach)	House	Did not advance (superseded by SB 45)	Rep. Jennifer Dailey-Provost (D) (sponsor per search; unconfirmed)
HB 301	Drug Recodification	House	Enrolled	Sponsor unconfirmed (text)
(unconfirmed bill no.)	CBD vape pen ban	unconfirmed	Passed	Sponsor unconfirmed (Fox 13)
(unconfirmed bill no.)	Expand medical cannabis dispensaries to tribes	Senate	Did not advance	Sen. Ron Winterton (R)
(unconfirmed bill no.)	Workers' compensation and medical cannabis patients	House	No hearing	Rep. Walt Brooks (R)

Support this work

This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.

If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.

Contribute $5 on Ko-fi Become a member

← Back to all 50 states and federal briefs

A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.

About the author. Jessica Mantonya is the founder of Drug Policy Watch and Hold in Common. She also advises operators, advocates, and funders on regulatory strategy and anti-enclosure positioning. Work with her →